- Home
- BALL vs ASND Comparison
BALL vs ASND Comparison
Compare BALL & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BALL | ASND |
|---|---|---|
| Founded | 1880 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 14.7B |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BALL | ASND |
|---|---|---|
| Price | $58.70 | $237.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $69.00 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 2.5M | 744.9K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.96 | $96.35 |
| Revenue Next Year | $3.51 | $44.91 |
| P/E Ratio | $76.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.83 | $153.49 |
| 52 Week High | $68.56 | $250.74 |
Technical Indicators
Market Signals| Indicator | BALL | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 53.65 |
| Support Level | $56.63 | $215.18 |
| Resistance Level | $62.11 | $244.79 |
| Average True Range (ATR) | 1.73 | 10.10 |
| MACD | -0.44 | 0.89 |
| Stochastic Oscillator | 20.10 | 62.35 |
Price Performance
Historical ComparisonAbout BALL Ball Corporation
Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments-beverage packaging, North and Central America (48% of 2025 revenue), beverage packaging, EMEA (30%), beverage packaging, South America (16%)-and it generated $13 billion in revenue in 2025.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.